Creative Planning increased its position in Juno Therapeutics, Inc. (NASDAQ:JUNO) by 5.9% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 50,827 shares of the biopharmaceutical company’s stock after buying an additional 2,811 shares during the period. Creative Planning’s holdings in Juno Therapeutics were worth $1,519,000 as of its most recent filing with the SEC.
Other institutional investors also recently modified their holdings of the company. Great West Life Assurance Co. Can boosted its position in Juno Therapeutics by 80.5% in the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 3,800 shares during the period. Nisa Investment Advisors LLC acquired a new position in Juno Therapeutics during the first quarter valued at $200,000. Russell Investments Group Ltd. acquired a new position in Juno Therapeutics during the fourth quarter valued at $204,000. Tudor Investment Corp Et Al acquired a new position in Juno Therapeutics during the fourth quarter valued at $215,000. Finally, Opus Point Partners Management LLC boosted its position in Juno Therapeutics by 65.9% in the fourth quarter. Opus Point Partners Management LLC now owns 11,478 shares of the biopharmaceutical company’s stock valued at $216,000 after buying an additional 4,560 shares during the period. 64.60% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Juno Therapeutics, Inc. (NASDAQ JUNO) traded up 1.86% during mid-day trading on Friday, reaching $28.49. The company’s stock had a trading volume of 722,929 shares. The firm’s market cap is $2.99 billion. The firm has a 50 day moving average price of $29.03 and a 200 day moving average price of $24.53. Juno Therapeutics, Inc. has a 52-week low of $17.52 and a 52-week high of $35.04.
Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by $0.24. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The business had revenue of $21.30 million during the quarter, compared to the consensus estimate of $15.59 million. During the same quarter in the previous year, the business posted ($0.64) EPS. The company’s revenue for the quarter was down 22.8% on a year-over-year basis. On average, equities analysts predict that Juno Therapeutics, Inc. will post ($3.13) EPS for the current fiscal year.
Several research firms have weighed in on JUNO. Zacks Investment Research cut Juno Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 2nd. Morgan Stanley lifted their target price on Juno Therapeutics from $26.00 to $27.00 and gave the company an “equal weight” rating in a research note on Monday. FBR & Co reaffirmed a “hold” rating on shares of Juno Therapeutics in a research note on Thursday, May 18th. Vetr cut Juno Therapeutics from a “buy” rating to a “hold” rating and set a $28.85 price target for the company. in a research note on Monday, June 26th. Finally, Wedbush reissued a “neutral” rating and issued a $24.00 price target on shares of Juno Therapeutics in a research note on Friday, May 5th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $30.86.
In other Juno Therapeutics news, Director Anthony B. Evnin purchased 9,000 shares of the firm’s stock in a transaction dated Tuesday, June 20th. The shares were bought at an average price of $24.40 per share, for a total transaction of $219,600.00. Following the purchase, the director now owns 66,301 shares in the company, valued at approximately $1,617,744.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jay T. Flatley purchased 20,000 shares of the firm’s stock in a transaction dated Friday, May 26th. The stock was acquired at an average price of $24.76 per share, for a total transaction of $495,200.00. The disclosure for this purchase can be found here. In the last quarter, insiders sold 8,053,500 shares of company stock worth $217,594,440. Corporate insiders own 15.26% of the company’s stock.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
What are top analysts saying about Juno Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Juno Therapeutics Inc. and related companies.